Is Carticel right for my patient?
Carticel is a viable treatment option for the appropriate patient.
- With articular cartilage damage in the femoral condyle (medial, lateral, trochlea) caused by acute and repetitive trauma.
- Who have failed a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).
Frequently, an articular cartilage defect may be identified based on a patient’s symptoms and clinical evaluation, or may be identified during surgical treatment for another procedure such as ACL or meniscal repair.
Patient motivation and expectations, including commitment to rehabilitation, should be considered when determining if Carticel is the right choice for your patient.
Use of Carticel in children, patients over age 65, or in joints other than the knee has not yet been assessed.
Here are some additional factors for physicians and healthcare professionals to consider:
- Has the patient been treated for a prior cartilage repair procedure, such as debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft?
- Did the patient receive an optimal result from the first procedure? For example, has the patient been able to return to the activities they desire since a prior treatment for the cartilage defect?
- Has the patient compromised or altered their daily activities and/or their ability to participate in sports due to pain or other symptoms?
- What are the patient’s expectations regarding return to function?
- Is this patient willing to comply with rehabilitation requirements?
- Is the joint stable, with good alignment and greater than 50% of the meniscus in the compartment?
- Joint malalignment, ligament instability/deficiency or meniscal pathology should be treated prior to or concomitantly with Carticel implantation.
- The joint should be relatively healthy and the defect should be contained or partially contained by healthy surrounding cartilage.
- Patients with osteoarthritis should not be considered for Carticel implantation.
- Carticel has shown good clinical outcomes in larger lesions as shown in both the STAR and Registry Study.
- What is the size of the defect? There is no size restriction on lesions treated with Carticel.
- Is there bony involvement? Carticel has demonstrated efficacy in treating patients with osteochondritis dissecans (OCD).
- Where is the defect located? Carticel is approved to treat articular cartilage injuries in the femoral condyle (medial, lateral, trochlea).